Brilinta tabs 90mg #168

Brilinta instruction

You can buy Brilinta on this page

In addition to the main mechanism of action in the human body, ticagrelor also has an auxiliary one. In organs that do not have enough oxygen, as well as in tissues that have damage of a different nature, adenosine is formed through the release from adenosine diphosphate and adenosine triphosphate. It has properties such as relaxation of the muscles of the blood vessels, slowing down the destruction of myocardial cells. Thanks to the effects of ticagrelor, the content of adenosine in the human body increases and its therapeutic effect is prolonged.
The drug has a high bioavailability. The targeted action begins already half an hour after administration. Brilinta reaches its maximum content in the human body within a maximum of four hours from the moment of application.

Composition and form of release

For the production of Brilinta's medicine, the following components are used:
    the active ingredient is ticagrelor;
    excipients in the form of sodium carboxymethyl starch, magnesium stearate, calcium hydrogen phosphate, hydroxypropyl cellulose, mannitolum; ...
    a film casing consisting of talc, methoxypropyl cellulose, polyethylene glycol, food additive E172, titanium dioxide.
The manufacturer produces a medicine in the form of tablets with a dosage of the active ingredient of 90 milligrams. The tablets are round with bulges on both sides. The color of the tablets is yellow. One side of the tablet is engraved with a large "T" and the number "90". Their primary packaging is polyvinyl chloride blister packs containing fourteen tablets. Blister plates in the amount of one, four or twelve pieces, together with instructions for use, are packed in cardboard boxes.

Indications for use

Brilinta is prescribed as part of complex therapy as a preventive measure to prevent the formation of blood clots in blood vessels in patients of the following categories:
    having violations of the blood supply to the heart muscle caused by myocardial infarction;
    underwent balloon angioplasty;
    who have undergone a bypass surgery of the heart.

Side effects

Side effects after using Brilinta can occur from various body systems. Below they are presented depending on the frequency of occurrence.
Often:
    labored breathing;
    bleeding from the nose;
    bleeding in the gastrointestinal tract;
    a collection of blood under the skin.
Infrequently:
    hemorrhage in the skull;
    dizziness, migraine;
    bleeding in the cornea of ​​the eye;
    hemoptysis;
    bleeding from the rectum;
    inflammation of the stomach lining;
    a feeling of nausea, turning into vomiting;
    frequent loose stools;
    accumulation of gas in the intestines;
    pain in the abdominal region;
    bleeding from the urinary tract;
    allergic reactions in the form of rashes, burning, itching;
Seldom:
    increased concentration of uric acid in the blood;
    tingling in the limbs;
    concentration disorders;
    disorientation in space
    violation of defecation;
    bleeding in the joints;
    swelling of the face.

Contraindications

The drug should not be used if one of the following contraindications is present:
    hypersensitivity to individual components present in the composition of the medication;
    risk of hemorrhage;
    problems with blood clotting;
    increased blood pressure in the chronic phase;
    violation of the liver in an acute form;
    violation of the kidneys in an acute form;
    taking medications that prevent active blood clotting;
    the period of pregnancy due to the lack of objective clinical information;
    the period of breastfeeding due to the lack of objective clinical information;
    children under eighteen years of age due to the lack of objective clinical information.

Pregnancy and lactation

Currently, there is a limited amount of information regarding the effect of Brilinta on the course of pregnancy, therefore, it is not recommended for pregnant women to use it. In the course of preclinical tests, it was revealed that in animals, the active ingredient of the drug is excreted in breast milk in high concentration. Therefore, its use during lactation is not recommended.
No adverse effects on fertility have been identified.

Application: method and features

Brilinta's drug is taken orally, regardless of food intake. The therapeutic course, as a rule, should begin with the use of one dose equal to two tablets. Each subsequent intake of the drug must follow the scheme: one tablet twice within twenty-four hours in the morning and evening. It is not recommended to miss the set time for the use of tablets. In case of a pass, it is forbidden to use the medicine at an unspecified time. The next reception should be carried out according to the schedule.
If the swallowing reflex is disturbed, it is allowed to crush the tablet to a fine powder and dilute the resulting product in one hundred and fifty grams of water. After dilution, you should immediately drink the ready-made solution, the remnants of which, after stirring in a similar volume of liquid, also immediately drink. It is possible to deliver the medication to the stomach by means of a special food probe.
As a rule, the therapeutic course with Brilinta is not complete with the use of only one drug. In the absence of adverse reactions, treatment with this medication is accompanied by acetylsalicylic acid.
The duration of use of Brilinta tablets should be at least one year. The possibility of using the medication for more than one year has not been fully studied, and therefore it is not recommended. In the case of a sharp withdrawal of the drug, serious disturbances in the work of the cardiovascular system are possible, up to a lethal outcome.

Alcohol compatibility

It is not recommended to consume alcoholic beverages during a therapeutic course.

Interaction with other medicinal products

Combined use with simvastatin and atorvastatin significantly increases the content of these drugs in the patient's body.
Brilinta has no effect on the pharmacological properties of oral contraceptives.
In the case of concomitant use with P-glycoproteins, their maximum content may be increased by three times. No effect on ticagrelor was observed. If necessary, joint use is required to conduct appropriate clinical studies.
Does not interact with acetylsalicylic acid.
Medicines aimed at lowering acidity in the stomach reduce the bioavailability of Brilinta.

Overdose

Subject to the manufacturer's prescribed dose, overdose was not detected.
At the same time, studies have shown that an overdose of medication can manifest itself as disturbances in the work of the digestive tract. There may also be increases from side effects, including difficulty breathing and hemorrhage.
There is no antidote, therefore, in the event of an overdose, you must immediately contact your doctor for symptomatic therapy.

Special instructions

The passage of a therapeutic course with this medication should be accompanied by strict supervision of a competent specialist for the timely elimination of potential hemorrhages.
If there is a suspicion of the development of bleeding in a patient, appropriate blood tests are required immediately.
Patients with ischemic heart disease have a greater risk of bleeding during the period of use of Brilinta.
Care should be taken when prescribing medication to people who have an increased risk of hemorrhage and who are taking drugs aimed at inhibiting blood clotting.
It is recommended, if possible, to exclude the combined use of Brilinta with drugs that affect blood clotting.
Not recommended for use by patients with liver diseases leading to bleeding disorders.
In the case of planned surgical interventions, suspend the use of the medication at least one week before the expected date of the operation.
It does not affect driving or engaging in activities requiring increased attention.

Storage rules, shelf life

Brilinta should be stored in a place protected from sunlight at a temperature of less than twenty-five degrees Celsius for no more than three years.

Reviews of the drug

Patient reviews on the use of Brilinta are mostly positive. The high efficiency of the drug is noted when used together with acetylsalicylic acid in the post-infarction period. There are practically no side effects. Negative reviews are associated with the high price of the drug.

Terms of sell

You don't need a prescription from a doctor to buy Brilinta.